Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

Researchers conducted a retrospective cohort study of 34,248 women diagnosed with locoregional breast cancer who received ...

For patients with resected stage IB-IIIA epidermal growth factor receptor-mutated non-small cell lung cancer, molecular ...

Researchers studying over 2,000 Ashkenazi Jewish centenarians uncovered two rare IGF-1 gene variants linked to exceptional ...

General and administrative expense for the year ended December 31, 2024 increased to $4.7 million, compared to $4.2 million for the year ended December 31, 2023 primarily due to increased salaries and ...

Charles Schwab Investment Management Inc. bought a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX – Free ...

Focused on the evaluation of strategic alternativesAdopted a restructuring plan to extend capital resources, incurring a reduction in workforce ...

Now, findings of a recent multicenter study led by Mariella Filbin, MD, PhD, co-director of the Brain Tumor Center at Boston Children’s Hospital and Dana-Farber Cancer Institute, suggest that PDGFRA ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Lytgobi is an FGFR inhibitor that received accelerated approval in 2022 to treat adults with previously treated, unresectable ...